- US FTC requests more information from both parties
- Both companies committed to the transaction
F. Hoffmann-La Roche AG’s (SIX: RO), better known as Roche’s, planned takeover of the pharmaceutical company Spark Therapeutics (NASDAQ: ONCE) has been delayed after the U.S. Federal Trade Commission requested more information on the deal from both companies.
“The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC in connection with its review,” Roche said in a statement.
Previously, Roche’s agreed a $4.3 billion deal to acquire Spark.